Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 6/20 | 0.74 |
| ▸ | GHSR | Q92847 | 5/20 | 0.54 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23753696 | 0.96 | FASN (0.78) | FASNGHSRMAP3K11MAPK14GPR183 | |
| SCHEMBL23753682 | 0.88 | FASN (0.70) | FASNGHSRMAP3K11MAPK14GPR183 | |
| SCHEMBL23753680 | 0.88 | FASN (0.91) | FASNGHSRMAP3K11MAPK14 | |
| SCHEMBL17389957 | 0.85 | FASN (1.00) | FASNGHSRMAP3K11 | |
| SCHEMBL17389748 | 0.81 | FASN (0.49) | FASNGPR183 | |
| SCHEMBL17389828 | 0.81 | FASN (0.49) | FASNGHSR | |
| SCHEMBL23753712 | 0.80 | FASN (0.82) | FASNGHSRMAP3K11MAPK14GPR183 | |
| SCHEMBL17389620 | 0.80 | FASN (0.48) | FASNGHSRMAP3K11 | |
| SCHEMBL17411164 | 0.78 | FASN (0.49) | FASN | |
| SCHEMBL17390054 | 0.76 | FASN (0.52) | FASNGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | CORNELL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252011-A1 | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | AIFM2, FABP7, FASN | FASN 3/4885GHSR 2921/4885MAP3K11 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.